US 12,458,635 B2
Pharmaceutical composition and administrations thereof
William Rowe, Medford, MA (US); Patricia Hurter, Harvard, MA (US); Christopher Young, Waltham, MA (US); Kirk Dinehart, Holliston, MA (US); Marinus Jacobus Verwijs, Framingham, MA (US); Kirk Overhoff, Waltham, MA (US); Peter D. J. Grootenhuis, San Diego, CA (US); Martyn Botfield, Concord, MA (US); and Alfredo Grossi, Somerville, MA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Dec. 30, 2022, as Appl. No. 18/091,476.
Application 16/842,480 is a division of application No. 15/253,636, filed on Aug. 31, 2016, granted, now 10,646,481, issued on May 12, 2020.
Application 18/091,476 is a continuation of application No. 16/842,480, filed on Apr. 7, 2020, granted, now 11,564,916.
Application 15/253,636 is a continuation of application No. 14/135,323, filed on Dec. 19, 2013, abandoned.
Application 14/135,323 is a continuation of application No. 12/583,066, filed on Aug. 13, 2009, abandoned.
Claims priority of provisional application 61/183,345, filed on Jun. 2, 2009.
Claims priority of provisional application 61/181,527, filed on May 27, 2009.
Claims priority of provisional application 61/146,163, filed on Jan. 21, 2009.
Claims priority of provisional application 61/090,096, filed on Aug. 19, 2008.
Claims priority of provisional application 61/088,801, filed on Aug. 14, 2008.
Claims priority of provisional application 61/088,704, filed on Aug. 13, 2008.
Prior Publication US 2023/0210839 A1, Jul. 6, 2023
Int. Cl. A61K 31/47 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/44 (2006.01)
CPC A61K 31/47 (2013.01) [A61K 9/0053 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/28 (2013.01); A61K 9/2813 (2013.01); A61K 9/282 (2013.01); A61K 9/2826 (2013.01); A61K 9/284 (2013.01); A61K 9/2853 (2013.01); A61K 9/2866 (2013.01); A61K 31/44 (2013.01)] 17 Claims
 
1. A pharmaceutical composition comprising a single solid dispersion, wherein the solid dispersion comprises:
i. about 80 wt % of amorphous or substantially amorphous N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) by weight of the solid dispersion, wherein the substantially amorphous Compound 1 comprises less than about 15% crystalline Compound 1;
ii. about 19.5 wt % of hydroxypropylmethylcellulose acetate succinate (HPMCAS) by weight of the solid dispersion; and
iii. about 0.5 wt % of sodium lauryl sulfate (SLS) by weight of the solid dispersion.